Dr. Daniel D. Esmaili, M.D.
Ophthalmology (Ophthalmology Physician)
9001 Wilshire Blvd Ste 301
Beverly Hills, CA 90211
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,050
Licensed in California since 2005, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Southern California Keck School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
CA license A91049 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Pih Health Good Samaritan Hospital Los Angeles, CA
Medical groups
- Pacific Eye Institute A Medical Group Inc (44 clinicians)
- Retina-Vitreous Associates Medical Group PC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,050
- Services billed
- 34,231
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 8,220 | 38 |
| Imaging of retina | 3,155 | 991 |
| Established patient complete exam of visual system | 2,212 | 826 |
| Injection, aflibercept, 1 mg | 1,978 | 164 |
| Injection of drug into eye | 1,952 | 329 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,508 | 85 |
| Established patient problem focused exam of visual system | 668 | 192 |
| Injection, bevacizumab, 10 mg | 530 | 105 |
| Extended exam of the back part of the eye with retinal drawing | 384 | 305 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 330 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Beverly Hills, CA | 66 |
| Latanoprost Other prescribers in Beverly Hills, CA | 60 |
| Ketorolac Tromethamine Other prescribers in Beverly Hills, CA | 51 |
| Brimonidine Tartrate Other prescribers in Beverly Hills, CA | 48 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Beverly Hills, CA | 45 |
| Timolol Maleate Other prescribers in Beverly Hills, CA | 26 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Beverly Hills, CA | 23 |
| Ofloxacin Other prescribers in Beverly Hills, CA | 19 |
| Atropine Sulfate | 18 |
| Eylea (aflibercept) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 15 payments worth $395 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $192 |
|---|---|
| AbbVie Inc. | $172 |
| Alcon Vision LLC | $30.16 |
| Food and Beverage | $395 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,933 in research payments for these studies, mostly to the institutions running them.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.